14
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10096L | Voruciclib | CDK | |
Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM). Voruciclib represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma. Voruciclib effectively blocks CDK9, the ... | |||
T16040 | Mepazine | Pecazine | Apoptosis , MALT |
Mepazine (Pecazine) is a potent and selective inhibitor of MALT1. Mepazine inhibits GSTMALT1 full length and GSTMALT1 325-760 with IC50s of 0.83 μM and 0.42 μM. Mepazine enhances apoptosis and affects the cell viability. | |||
T5354 | IRAK4-IN-7 | CA-4948 | IRAK |
IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model. | |||
T14367 | AZ1495 | IRAK , CDK , Haspin Kinase | |
AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffu... | |||
T3549 | Avadomide | CC 122 | Apoptosis , E1/E2/E3 Enzyme , Ligand for E3 Ligase |
Avadomide (CC 122) is an orally available pleiotropic pathway modulator with potential antineoplastic activity. | |||
T77367 | Urelumab | BMS-663513,BMS-66513 | Others |
Urelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.Urelumab has potential antitumor activity, potentiating tumor cell killing by T-cells and natural killer cells, and enhancing the... | |||
T77940 | Tazemetostat de(methyl morpholine)-COOH | Ligands for Target Protein for PROTAC | |
Tazemetostat de(methyl morpholine)-COOH (compound 7), a PROTAC ligand for EZH2, facilitates the synthesis of PROTACs that target this enzyme. These EZH2 degraders exhibit potent inhibition of cell viability in diffuse la... | |||
T77070 | Loncastuximab | ||
Loncastuximab (RB4v1.2), an anti-CD19 monoclonal antibody, exhibits antitumor properties and holds potential for treating non-Hodgkin's lymphoma (NHL), specifically diffuse large B-cell lymphoma (DLBCL) [1] [2]. | |||
T73869 | BCL6 PROTAC 1 | ||
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) proteolysis targeting chimera (PROTAC) that inhibits the BCL6 cell reporter with an IC50 value of 8.8 µM and significantly degrades BCL6 in diffuse large B-cell lymph... | |||
T79485 | IRAK4-IN-27 | IRAK | |
IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor, demonstrating an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) c... | |||
T81696 | NBI-961 | ||
NBI-961, a potent NEK2 inhibitor, suppresses proteasomal degradation and effectively induces G2/mitosis arrest and apoptosis within diffuse large B cell lymphoma (DLBCL) cells [1]. | |||
T62403 | DM-01 | ||
DM-01 is a potent and selective inhibitor of EZH2. DM-01 can be used to study diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and SNF5/INI-1/SMARCB1 gene-associated solid tumours. | |||
T26688 | Avadomide HCl | Avadomide hydrochloride,CC122, Avadomide HCl,CC-122,CC 122 HCl | |
Avadomide is an orally available pleiotropic pathway modulator with potential antineoplastic activity. CC-122 mimics an interferon response and has antitumor activity in DLBCL CC-122 binds Cereblon (CRBN) and promotes de... | |||
T79801 | TCIP 1 | Epigenetic Reader Domain | |
TCIP 1 is a small molecule in the category of transcriptional/epigenetic covalent inhibitor probes (TCIPs) that forms covalent bonds with molecules targeting BCL6 and BRD4. This compound facilitates cell death gene expre... |